BY ANJA HAUGE
-
Demant boosts top line in challenging second quarter
The firm is starting a restructuring prepare for the EPOS service.
-
FDA grants Bavarian Nordic vaccine priority review status
The vaccination uses security versus the chikungunya infection, and will certainly currently be authorized or denied by the FDA by February 2025.
-
Demant financial results ahead: Keep an eye on the details
In July, Demant took a few of the thriller out of the economic declarations by, to name a few points, offering a descending modification.
-
PMCPA ruling: Novo Nordisk CEO has “reduced confidence in” the industry
Lars Fruergaard Jørgensen called Wegovy a “expect individuals coping with weight problems” in the British Sunday Times. According to the board, this declaration has act…
-
Zepbound hot on Wegovy’s heels with 40% US market share
Medical professionals are suggesting the medications they believe are readily available at drug stores, Reuters records.
-
Genmab not looking for new partner after Biontech left cancer asset collaboration
Genmab will proceed the event of a lung most cancers drug by itself after Biontech has left the collaboration, the CEO defined on Thursday.
-
Genmab upgrades sales guidance
Both leading and profits expanded in the quarter.
-
Zealand Pharma appoints new Commercial Director
The corporate has appointed Eric Cox to the place as of August 5.
-
Novo Nordisk gets part of Novoseven lawsuit dismissed
The business is implicated of unlawfully raising the variety of prescriptions created for the hemophilia therapy item.
-
Genmab’s CEO steps down from Leo Pharma’s board of directors
His main profession at Genmab needs even more time, he states.